Toronto, Canada (PRWEB) November 29, 2012
With strict R&D budgets and increasing regulatory hurdles, in addition to the particularly high failure rate of Phase 3 studies in oncology, setting the right course early in clinical development is critical.
In this exciting Xtalks webinar, esteemed speakers from Quintiles, including Philip Breitfeld, MD, Vice President, Therapeutic Strategy, Oncology Therapeutic Area, Eric Groves, MD, PhD, Vice President, Center for Integrated Drug Development, and Chris Learn, PhD, PMP, Senior Clinical Project Manager, will provide valuable insights for better decision making in the early development of oncology compounds.
In fact, attendees can expect to gain:
For more information about this event or to register, visit: http://xtks.in/xto-548p
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx
Karen Lim (416) 977-6555 ext 227